A Phase 1, Open-Label, 2-Period, 2-Formulation, Within-Subject Crossover Comparative Pharmacokinetic, Pharmacodynamic, and Safety Study of 1 Dose Level of Aspirin for Injection and Oral Aspirin Tablets in Healthy Adult Human Subjects Under Fasting Conditions.

2025-521615-39-00 Protocol RHO-11-003 Human pharmacology (Phase I) - Other Ended

Start 4 Jun 2025 · End 14 Jul 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol RHO-11-003

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 40
Countries 1
Sites 1

not applicable (submitted trial is a pharmacokinetic and pharmacodynamic safety study in healthy subjects)

Key facts

Sponsor
Rhoshan Pharmaceuticals Inc.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Hemic and Lymphatic Diseases [C15]
Trial duration
4 Jun 2025 → 14 Jul 2025
Decision date (initial)
2025-06-03
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

not applicable (submitted trial is a pharmacokinetic and pharmacodynamic safety study in healthy subjects)

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Rhoshan Pharmaceuticals Inc.

Sponsor organisation
Rhoshan Pharmaceuticals Inc.
Address
2472 Pine Hurst Court
City
State College
Postcode
16803-3394
Country
United States

Scientific contact point

Organisation
Rhoshan Pharmaceuticals Inc.
Contact name
JOSEPH PURVIS, MD

Public contact point

Organisation
Rhoshan Pharmaceuticals Inc.
Contact name
HITHA PALEPU

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Czechia Ended 40 1
Rest of world 0

Investigational sites

Czechia

1 site · Ended
Quinta-Analytica s.r.o.
Clinical Unit, Prazska 1486/18c, Hostivar, Prague

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Czechia 2025-06-04 2025-07-14 2025-06-04 2025-06-23

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-04-22 Czechia Acceptable
2025-06-03
2025-06-03